These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 9789022)

  • 1. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.
    Peterson SA; Klabunde T; Lashuel HA; Purkey H; Sacchettini JC; Kelly JW
    Proc Natl Acad Sci U S A; 1998 Oct; 95(22):12956-60. PubMed ID: 9789022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovering transthyretin amyloid fibril inhibitors by limited screening.
    Baures PW; Peterson SA; Kelly JW
    Bioorg Med Chem; 1998 Aug; 6(8):1389-401. PubMed ID: 9784876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
    Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting transthyretin amyloid fibril formation via protein stabilization.
    Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
    Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
    J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
    Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
    Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
    Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
    Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P
    Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative stabilization of transthyretin by clusterin and diflunisal.
    Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
    Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
    Hammarström P; Jiang X; Deechongkit S; Kelly JW
    Biochemistry; 2001 Sep; 40(38):11453-9. PubMed ID: 11560493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of potent human transthyretin amyloid disease inhibitors.
    Klabunde T; Petrassi HM; Oza VB; Raman P; Kelly JW; Sacchettini JC
    Nat Struct Biol; 2000 Apr; 7(4):312-21. PubMed ID: 10742177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
    Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
    FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
    Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
    Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
    Rodrigues JR; Simões CJ; Silva CG; Brito RM
    Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.
    Quintas A; Saraiva MJ; Brito RM
    FEBS Lett; 1997 Dec; 418(3):297-300. PubMed ID: 9428731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro.
    McCutchen SL; Kelly JW
    Biochem Biophys Res Commun; 1993 Dec; 197(2):415-21. PubMed ID: 8267575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
    Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
    FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.